___

• Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43-6.
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five conti- nents: Defining priorities to reduce cancer disparities in different geographic response of the world. J Clin Oncol 2006; 24:2137-50.
• Day NE, Varghese C. Oesophageal cancer. Cancer Surv 1994; 19-20:43-54.
• Cejas P, Casado E, Belda-Iniesta C et al. Implications of oxidative stress and cell membrane lipid peroxida- tion in human cancer (Spain). Cancer Causes Control 2004;15:707-19.
• Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003; 31(Pt 6):1441–4.
• Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo- Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possi- ble peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581–90.
• Li Hl, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81:766-79.
• Schiavon R, Battaglia P, De Fanti E et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324:39-44.
• Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraox- onase levels in gastric cancer. Hepatogastroenterology 2003; 50 (Suppl 2):cclxxiii-cclxxv.
• Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003; 50 (Suppl 2):ccxxv-ccxxvii.
• Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;15:48.
• Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/ arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43:230-8.
• Eckerson HW, Wyte CM, La Du BN . The Human Serum Paraoxonase/Arylesterase Polymorphism. Am J Hum Genet 1983; 35:1126-38.
• Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in can- cer. Mutat Res 2001; 477:7-21.
• Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994; 63:915- 48.
• Cathcart MK, McNally AK, Chisolm GM. Lipoxygenase- mediated transformation of human low density lipopro- tein to oxidized and cytotoxic complex. J Lipid Res 1991; 32:63-70.
• Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of teh human serum paraox- onase polymorphism is reserved with diazoxon and sarin. Nat Genet 1996; 14:334-6.
• Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with in- creased macrophage oxidative stres: studies in PON1- knockout mice. Free Radic Biol Med 2003; 34:774-84.
• Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T. Paraoxonase 192 gene polymorphism and serum para- oxonase activity in high grade gliomas and menegiomas. Cell Biochem Funct 2006; 24:455-60.
• Lee CH, Lee KY, Choe KH et al. Effects of oxidative DNA damage induced by polycylic aromatic hydrocarbons and genetic polymorphism of theparaoxonase -1 (PON1) gene on lung cancer. Prev Med Pub Health 2005; 38:345-50.
• Marchesani M, Hakkarainen A, Tuomainen TP et al. New paraoxonase 1 polymorphism II02V and the risk of pros- tate cancer in Finnish men. J Natl Cancer Inst 2003; 95:812-8.
• Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP 17, GSTPI and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005; 63:240- 51.
• Van Der Logt EM, Janssen CH, Van Hooijdonk Z et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 2005; 25:1465-70.